BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated immunoassays and against a VDSP-traceable liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in six different populations. We also supplemented 40 healthy volunteers with either 600,000 IU ofvitamin D2 or 100,000 of vitamin D3 to evaluate the performance of the immunoassays vs. the LC-MS/MS. METHODS:Precision and limit of quantification were assessed, 25(OH)D2 and C3-epimer recovery were calculated. Two hundred and forty samples obtained in healthy Caucasians and Africans, osteoporotic, hemodialyzed and intensive care patients and 3rd trimester pregnant women were analyzed by all methods. Correlation was studied using Passing-Bablok and Bland-Altman analysis. Concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and LC-MS/MS. We verified if patients were homogeneously classified with the immunoassays when they took vitamin D2 or vitamin D3 after 1, 7 and 28 days. RESULTS: We observed excellent analytical features and showed a very good correlation to the LC-MS/MS results in the overall population. Compared to the other immunoassays, concordance of the new Abbott assay with the LC-MS/MS was at least similar, and often better in diseased populations. Althought the cross-reactivity with 25(OH)D2 was not of 100%, there was no significant difference in the classifications of the patients, either supplemented with D2 or D3 or after 7 or 28 days. CONCLUSIONS: This modified version of the Abbott Architect assay is clearly improved compared to the previous one and presents a better agreement with the LC-MS/MS.
RCT Entities:
BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated immunoassays and against a VDSP-traceable liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in six different populations. We also supplemented 40 healthy volunteers with either 600,000 IU of vitamin D2 or 100,000 of vitamin D3 to evaluate the performance of the immunoassays vs. the LC-MS/MS. METHODS: Precision and limit of quantification were assessed, 25(OH)D2 and C3-epimer recovery were calculated. Two hundred and forty samples obtained in healthy Caucasians and Africans, osteoporotic, hemodialyzed and intensive care patients and 3rd trimester pregnant women were analyzed by all methods. Correlation was studied using Passing-Bablok and Bland-Altman analysis. Concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and LC-MS/MS. We verified if patients were homogeneously classified with the immunoassays when they took vitamin D2 or vitamin D3 after 1, 7 and 28 days. RESULTS: We observed excellent analytical features and showed a very good correlation to the LC-MS/MS results in the overall population. Compared to the other immunoassays, concordance of the new Abbott assay with the LC-MS/MS was at least similar, and often better in diseased populations. Althought the cross-reactivity with 25(OH)D2 was not of 100%, there was no significant difference in the classifications of the patients, either supplemented with D2 or D3 or after 7 or 28 days. CONCLUSIONS: This modified version of the Abbott Architect assay is clearly improved compared to the previous one and presents a better agreement with the LC-MS/MS.
Authors: Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley Journal: Br J Clin Pharmacol Date: 2018-07-17 Impact factor: 4.335
Authors: Stephen A Wise; Johanna E Camara; Carolyn Q Burdette; Grace Hahm; Federica Nalin; Adam J Kuszak; Joyce Merkel; Ramón A Durazo-Arvizu; Emma L Williams; Andrew N Hoofnagle; Fiona Ivison; Ralf Fischer; Jody M W van den Ouweland; Chung S Ho; Emmett W K Law; Jean-Nicolas Simard; Renaud Gonthier; Brett Holmquist; Sarah Meadows; Lorna Cox; Kimberly Robyak; Michael H Creer; Robert Fitzgerald; Michael W Clarke; Norma Breen; Pierre Lukas; Étienne Cavalier; Christopher T Sempos Journal: Anal Bioanal Chem Date: 2021-08-25 Impact factor: 4.142
Authors: Stephen A Wise; Johanna E Camara; Carolyn Q Burdette; Grace Hahm; Federica Nalin; Adam J Kuszak; Joyce Merkel; Ramón A Durazo-Arvizu; Emma L Williams; Christian Popp; Christian Beckert; Jan Schultess; Glen Van Slooten; Carole Tourneur; Camille Pease; Ravi Kaul; Alfredo Villarreal; Marcelo Cidade Batista; Heather Pham; Alex Bennett; Eugene Jansen; Dilshad Ahmed Khan; Mark Kilbane; Patrick J Twomey; James Freeman; Neil Parker; Sohail Mushtaq; Christine Simpson; Pierre Lukas; Étienne Cavalier; Christopher T Sempos Journal: Anal Bioanal Chem Date: 2021-08-25 Impact factor: 4.142
Authors: Barbara Altieri; Etienne Cavalier; Harjit Pal Bhattoa; Faustino R Pérez-López; María T López-Baena; Gonzalo R Pérez-Roncero; Peter Chedraui; Cedric Annweiler; Silvia Della Casa; Sieglinde Zelzer; Markus Herrmann; Antongiulio Faggiano; Annamaria Colao; Michael F Holick Journal: Eur J Clin Nutr Date: 2020-01-06 Impact factor: 4.016
Authors: Konstantinos Makris; Harjit P Bhattoa; Etienne Cavalier; Karen Phinney; Christopher T Sempos; Candice Z Ulmer; Samuel D Vasikaran; Hubert Vesper; Annemieke C Heijboer Journal: Clin Chim Acta Date: 2021-03-10 Impact factor: 6.314
Authors: Kristina Rueter; Lucinda J Black; Anderson Jones; Max Bulsara; Michael W Clarke; Cristina Gamez; Ee M Lim; Debra J Palmer; Susan L Prescott; Aris Siafarikas Journal: Int J Environ Res Public Health Date: 2020-01-08 Impact factor: 3.390
Authors: A Giustina; R A Adler; N Binkley; J Bollerslev; R Bouillon; B Dawson-Hughes; P R Ebeling; D Feldman; A M Formenti; M Lazaretti-Castro; C Marcocci; R Rizzoli; C T Sempos; J P Bilezikian Journal: Rev Endocr Metab Disord Date: 2020-03 Impact factor: 6.514